Handelsbanken Fonder’s Karyopharm Therapeutics KPTI Stock Holding History

Handelsbanken Fonder’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-693	Closed	-$61K	–	1751
2021 Q3	$61K	Hold	693	–	–	﹤0.01%	1675
2021 Q2	$107K	Sell	693 -200	-22%	-$29K	﹤0.01%	1703
2021 Q1	$141K	Hold	893	–	–	﹤0.01%	1554
2020 Q4	$207K	Hold	893	–	–	﹤0.01%	1515
2020 Q3	$196K	Hold	893	–	–	﹤0.01%	1391
2020 Q2	$254K	Buy	+893	New	+$264K	﹤0.01%	1296

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Handelsbanken Fonder's KPTI Position: Q4 2021 in Review

Handelsbanken Fonder sold out of Karyopharm Therapeutics (KPTI) in Q4 2021, closing a stake of 693 shares — an estimated $61K sold.

Handelsbanken Fonder first reported a position in KPTI in Q2 2020 and held it in 6 quarters. The position peaked at $254K in Q2 2020. 143 funds tracked by Wall St. Rank hold KPTI as of Q4 2021.

Handelsbanken Fonder reported no remaining Karyopharm Therapeutics position as of Q4 2021 after selling out during the quarter.
Handelsbanken Fonder sold 693 Karyopharm Therapeutics shares in Q4 2021, an estimated $61K.
Handelsbanken Fonder first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 6 quarters.
Handelsbanken Fonder's Karyopharm Therapeutics position peaked at $254K in Q2 2020.
143 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2021.

Based on Handelsbanken Fonder's 13F filing for Q4 2021, filed 8 Feb 2022.